SkinBioTherapeutics assessing options for a ‘rapid trial’ of its food supplement

SkinBioTherapeutics PLC (LON:SBTX) CEO Stuart Ashman tells Proactive London’s Andrew Scott they’re looking at all routes possible to get its psoriasis product into the hands of those that need it as they assesses options for a fast-track human study. It’s part of their collaboration with Winclove Probiotics which is well ahead of schedule. Ashman adds that their work with partner Croda to develop an active skincare ingredient is also making good progress.

Previous ArticleNext Article